A Phase 3, Rollover Study to Evaluate the Safety of Long-term Treatment With Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Dec 2017
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 18 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 30 May 2017 Status changed from not yet recruiting to recruiting.